Showing results (81-90 of 95) with videos related to

Sort By:
Pageof 10
RMD Open|August 19, 2023
Drug retention of biologics and Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort studyKosuke Ebina, Yuki Etani, Yuichi Maeda, et al.
Rheumatology (Oxford, England)|May 9, 2024
Predictive factors and treatment outcomes associated with difficult-to-treat rheumatoid arthritis conditions: the ANSWER cohort studyRyu Watanabe, Kosuke Ebina, Takaho Gon, et al.
Drug Discoveries & Therapeutics|August 24, 2025
Switching from originator infliximab to biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving clinical remission (the IFX-SIRIUS study I): An interventional, multicenter, open-label, single-arm clinical trial with clinical, ultrasound and biomarker assessmentsToshimasa Shimizu, Shin-Ya Kawashiri, Tomohiro Koga, et al.
Modern Rheumatology|March 19, 2025
Distinct impact of RF and ACPA titer on the effectiveness and persistency of biologics and JAK inhibitors: The ANSWER cohort studyYuki Etani, Yasutaka Okita, Yuichi Maeda, et al.
Frontiers in Immunology|February 16, 2026
Hepatocyte growth factor as a driver of synovial inflammation and therapeutic resistance in rheumatoid arthritisQuang Minh Dang, Ryu Watanabe, Takeshi Iwasaki, et al.
International Journal of Rheumatic Diseases|March 5, 2024
Association of large joint involvement at the start of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors with disease activity and drug retention in patients with rheumatoid arthritis: The ANSWER cohort studyIku Shirasugi, Akira Onishi, Keisuke Nishimura, et al.
International Journal of Rheumatic Diseases|July 1, 2025
Differential Impact of Concomitant Methotrexate and Glucocorticoids Dosages on Biologics and JAK Inhibitors: The ANSWER Cohort StudyKosuke Ebina, Yuki Etani, Yasutaka Okita, et al.
Rheumatology (Oxford, England)|November 4, 2023
Real-world comparative study of the efficacy of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort studyShinya Hayashi, Shotaro Tachibana, Toshihisa Maeda, et al.
Modern Rheumatology|April 7, 2022
Influence of concomitant methotrexate use on the clinical effectiveness, retention, and safety of abatacept in biologic-naïve patients with rheumatoid arthritis: Post-hoc subgroup analysis of the ORIGAMI studyTakanori Azuma, Kenta Misaki, Makio Kusaoi, et al.
Rheumatology International|May 9, 2022
Clinical characteristics of patients with spondyloarthritis and inflammatory bowel disease versus inflammatory bowel disease-related arthritisKeisuke Ono, Mitsumasa Kishimoto, Gautam A Deshpande, et al.
Pageof 10